醋酸阿比特龙片 | China Drugs ListAbiraterone acetate tablets | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

其他

商品名
Zytiga
企业
Janssen-Cilag International NV (欧盟上市许可持有人)Janssen-Cilag International NV (EU authorization holder)
药品类型
化学药Chemical medicine
治疗领域
肿瘤科Oncology
公开来源记录的适应症
欧盟来源摘要:与泼尼松或泼尼松龙联合,用于成年男性转移性前列腺癌:新诊断的高危激素敏感性疾病须同时采用雄激素剥夺治疗;雄激素剥夺治疗失败后无症状或症状轻微、尚无化疗指征的去势抵抗性疾病;或多西他赛治疗期间或之后进展的疾病。European Union source summary: For adult men with metastatic prostate cancer, used with prednisone or prednisolone: newly diagnosed high-risk hormone-sensitive disease with androgen deprivation therapy; castration-resistant disease after androgen deprivation failure when symptoms are absent or mild and chemotherapy is not yet indicated; or disease progressing during or after docetaxel.
适应症来源与口径
欧盟产品资料 查阅于 2026年11月2日; 未单独提取确切修订日期. 部分境外适应症;不确立中国批准范围。European Union product information accessed 2 November 2026; exact revision date not separately extracted.. Selected overseas indications; does not establish the Chinese approved scope.
说明书信息局限
已链接境外官方处方资料;尚未核实完整的现行中国说明书。Overseas official prescribing information linked; a complete current Chinese label has not been verified.
中国可获得性状态
本次英文来源核查未独立核实中国批准、现行批准适应症及持续在售情况。Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
海外状态
请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异;尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
医保分类
尚未核实Not yet verified
医保版本
中国国家医保信息待核实Chinese national insurance review pending
医保核查说明
本次新增记录尚未确定报销资格;缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.

来源

证据核查日期:

打开交互详情、公开价格与讨论